Dr Mef Durri Galle, MD | |
1825 Highway 34 E Ste 200, Newnan, GA 30265-6423 | |
(888) 341-3360 | |
Not Available |
Full Name | Dr Mef Durri Galle |
---|---|
Gender | Male |
Speciality | Specialist |
Location | 1825 Highway 34 E Ste 200, Newnan, Georgia |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053602599 | NPI | - | NPPES |
059722 | Other | GA | GEORGIA MEDICAL BOARD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | MD207562 (Oregon) | Secondary |
174400000X | Specialist | 59722 (Georgia) | Primary |
Entity Name | Wellstreet Of Georgia Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1235411547 PECOS PAC ID: 7517126279 Enrollment ID: O20120315000603 |
News Archive
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
Kaiser Health News staff writers Mary Agnes Carey and Julie Appleby talk with KFF's Jackie Judd about recent health policy developments, including the newly released Health and Human Services regulations dealing with the medical loss ratio and the status in Congress of the one-month patch to prevent physicians who see Medicare patients from having their payments reduced.
Less than 40 percent of people with severe elevations in cholesterol are being prescribed appropriate drug treatment, according to a nationally representative study reported in the American Heart Association's journal Circulation.
Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Mef Durri Galle, MD 1825 Highway 34 E Ste 200, Newnan, GA 30265-6423 Ph: (888) 341-3360 | Dr Mef Durri Galle, MD 1825 Highway 34 E Ste 200, Newnan, GA 30265-6423 Ph: (888) 341-3360 |
News Archive
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
Kaiser Health News staff writers Mary Agnes Carey and Julie Appleby talk with KFF's Jackie Judd about recent health policy developments, including the newly released Health and Human Services regulations dealing with the medical loss ratio and the status in Congress of the one-month patch to prevent physicians who see Medicare patients from having their payments reduced.
Less than 40 percent of people with severe elevations in cholesterol are being prescribed appropriate drug treatment, according to a nationally representative study reported in the American Heart Association's journal Circulation.
Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.
› Verified 4 days ago